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OBJECTIVES We sought to assess the relationship between completeness of revascularization and adverse
events at one year in the ARTS (Arterial Revascularization Therapies Study) trial.
BACKGROUND There is uncertainty to what extent degree of completeness of revascularization, using
up-to-date techniques, influences medium-term outcome.
METHODS After consensus between surgeon and cardiologist regarding the potential for equivalence in
the completeness of revascularization, 1,205 patients with multivessel disease were randomly
assigned to either bypass surgery or stent implantation. All baseline and procedural
angiograms and surgical case-record forms were centrally assessed for completeness of
revascularization.
RESULTS Of 1,205 patients randomized, 1,172 underwent the assigned treatment. Complete data for
review were available in 1,143 patients (97.5%). Complete revascularization was achieved in
84.1% of the surgically treated patients and 70.5% of the angioplasty patients (p  0.001).
After one year, the stented angioplasty patients with incomplete revascularization showed a
significantly lower event-free survival than stented patients with complete revascularization
(i.e., freedom from death, myocardial infarction, cerebrovascular accident and repeat
revascularization) (69.4% vs. 76.6%; p  0.05). This difference was due to a higher incidence
of subsequent bypass procedures (10.0% vs. 2.0%; p  0.05). Conversely, at one year, bypass
surgery patients with incomplete revascularization showed only a marginally lower event-free
survival rate than those with complete revascularization (87.8% vs. 89.9%).
CONCLUSIONS Complete revascularization was more frequently accomplished by bypass surgery than by stent
implantation. One year after bypass, there was no significant difference in event-free survival
between surgically treated patients with complete revascularization and those with incomplete
revascularization, but patients randomized to stenting with incomplete revascularization had
a greater need for subsequent bypass surgery. (J Am Coll Cardiol 2002;39:559–64) © 2002
by the American College of Cardiology
Randomized clinical trials indicate that both coronary an-
gioplasty and bypass surgery have the same outcome in
terms of irreversible events, such as mortality and myocar-
dial infarction, in patients with multivessel coronary artery
disease (1,2). The main difference in outcome relates to the
number of subsequent revascularizations after the index
procedure, which was 30% to 45% higher in the angioplasty
group at one year, as demonstrated in GABI (German
Angioplasty Bypass Intervention), ERACI (Estudio Ran-
domizado Argentino de Angioplastia vs. CIrurgia) and
CABRI (Coronary Angioplasty vs. Bypass Revasculariza-
tion Investigation) (3–5). After three to five years, these
differences in revascularization rates remain constant (2,6,7).
Over the past few years, there have been changes in both
the surgical and percutaneous techniques. The use of arterial
conduits during surgical revascularization and stent implan-
tation after balloon angioplasty have become standard treat-
ment. In the randomized trials mentioned earlier (2–7), the
intention to achieve equivalence in the completeness of
revascularization was required only in RITA (Randomized
Intervention Treatment of Angina), GABI and ERACI.
Nevertheless, the repeat intervention rate was not lower in
these trials than in those that accepted non-equivalence of
revascularization. Data on subgroups with complete or
incomplete revascularization have been published for the
BARI (Bypass Angioplasty Revascularization Investigation)
trial after five years and the CABRI trial after one year (8,9).
Neither BARI nor CABRI aimed at equivalent revascular-
ization, nor did they evaluate the completeness of revascu-
larization in the cohorts randomized to surgery.
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This report compares the differences in outcome in the
ARTS (Arterial Revascularization Therapies Study) trial of
bypass surgery versus percutaneous intervention between
subgroups that were completely or incompletely revascular-
ized, according to a central assessment of angiograms before
bypass surgery and before and after percutaneous interven-
tion. The general results of the ARTS trial have recently
been published (10).
METHODS
Patients. Patients were eligible for the ARTS trial if they
had stable or unstable angina or objective signs of ischemia
and multivessel disease, defined as at least two territories of
myocardium subtended by stenosed arteries (50% diame-
ter stenosis in a vessel with a reference diameter of at least
2.75 mm). After the surgeon and interventional cardiologist
agreed on the potential for equivalence in the degree of
completeness of revascularization with bypass surgery or
stented angioplasty, and after the patients gave written,
informed consent, the patients were randomly assigned to a
treatment group over the telephone by the central office of
the study. At least two of the three principal coronary
arteries—the left anterior descending (LAD), left circum-
flex (LCx) or right coronary artery (RCA)—had to require
revascularization. If the LCx was dominant, two or more
treatable lesions situated in this artery also satisfied the
inclusion criteria. Patients with previous angioplasty or
bypass surgery were excluded, as were patients with left
main coronary artery stenosis. A totally occluded vessel
estimated to be less than one month old, on the basis of
clinical history, could also be considered as a target vessel. If
the total occlusion was of unknown duration or known to be
present for more than one month, the patient could still be
included as long as two other lesions were targeted. Con-
ventional balloon angioplasty in vessels with 50% diame-
ter stenosis and a reference diameter between 1.50 and
2.75 mm was acceptable as long as two other vessels were
amenable to stenting. Lesion-specific criteria were not
defined for acceptability in this study. Patients with a left
ventricular ejection fraction30%, previous cerebrovascular
accident, recent infarction within the previous week or
concomitant severe hepatic or renal disease, or those who
needed additional major cardiac surgery, were excluded.
Surgical techniques for patients randomized to surgery
were also standardized. The LAD and/or diagonal branches
had to be revascularized using the left internal mammary
artery. Other vessels had to be bypassed with venous bypass
grafts.
Requirements for operators and institutions to qualify as
a participant in the ARTS trial, and additional guidelines
for medical treatment after either procedure, have previously
been published (11).
To evaluate the completeness of revascularization, all
patients initially treated according to randomization were
included. All pertinent diagnostic angiograms were re-
viewed centrally at Cardialysis, Rotterdam, The Nether-
lands, by two independent, experienced cardiologists (Drs.
van den Brand and Rensing). The coronary arteries were
subdivided into 15 segments according to the American
Heart Association/American College of Cardiology (AHA/
ACC) criteria (12). All lesions occupying50% diameter of
a segment with a reference diameter of 1.50 mm were
scored as potentially amenable to treatment. If all such
defined segments had been treated according to the surgical
report on the case-record form, the surgical procedure was
scored as a complete revascularization. If one or more
segments were left unbypassed, the patient was considered
to be incompletely revascularized. Any patient with grafts
bypassing one or more non-significant lesions and all
significant lesions was included in the completely revascu-
larized subgroup. Finally, patients treated with grafts by-
passing non-significant lesions, who also had significant
lesions that were left untreated, were considered to be
incompletely revascularized.
For patients randomized to stented angioplasty, both the
diagnostic and procedural angiograms were reviewed. The
procedure was considered to result in complete revascular-
ization if all lesions of 50% diameter stenosis had been
successfully treated. If no attempt was made to treat one or
more significant lesions, or if treatment resulted in a final
diameter stenosis 50%, these patients were considered to
be incompletely revascularized.
The degree of incompleteness of revascularization with
either technique was further specified by dividing coronary
artery segments into main and side branches. The proximal
LAD (segments 6 and 7), proximal LCx (segment 11 and,
in case of left dominance, segment 13) and proximal RCA
(segments 1, 2 and 3) were scored as main branches. All
other segments were scored as side branches (12). The
completeness of revascularization was then scored for the
main branches, the side branches or a combination of such
defined vessels.
The primary end point was freedom from any of the
following major adverse cardiac or cerebrovascular events:
death from any cause; cerebrovascular accident; documented
non-fatal myocardial infarction; and any revascularization
after the index procedure. For this substudy, events were
counted beginning at the index procedure.
Statistical analysis. Continuous variables were expressed
as the mean value  SD and were compared using the
unpaired Student t test. The Fisher exact test was used for
categorical variables. The Wilcoxon scores were used for
categorical variables, with an ordinal scale. Discrete vari-
ables were expressed as counts and percentages and com-
Abbreviations and Acronyms
ARTS  Arterial Revascularization Therapies Study
LAD  left anterior descending coronary artery
LCx  left circumflex coronary artery
RCA  right coronary artery
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pared in terms of relative risks with 95% confidence inter-
vals, calculated by the formula of Greenland and Robins
(13). All statistical tests were two-tailed. Event-free survival
was calculated according to the Kaplan-Meier method, and
differences were assessed using the log-rank test.
RESULTS
Between April 1997 and June 1998, 1,205 patients were
randomly assigned to stented angioplasty (n  600) or
bypass surgery (n  605) at 67 participating centers.
Excluding patients who died while on the waiting list
(n  3), received medical treatment only (n  5) or crossed
over to the opposite treatment (n  25), a total of 1,172
patients were treated according to their assigned procedure:
593 stented angioplasty and 579 bypass patients. Angio-
grams from 1,143 patients (97.5%) were available for central
analysis. For stented angioplasty, 576 (97.1%) of 593 an-
giograms could be reviewed, whereas for bypass surgery, 567
(97.9%) of 579 angiograms were available.
Baseline demographic data and patient characteristics for
subjects included in the analysis of complete and incomplete
revascularizations are summarized in Table 1. Complete
revascularization was achieved in 84.1% of bypass surgery
patients and in 70.5% of stented angioplasty patients (p 
0.001). Incompletely revascularized patients from both
groups showed a significantly higher number of diseased
vessels and segments, compared with completely revascular-
ized patients (Table 2).
The number of segments treated in the groups that were
incompletely revascularized was lower than the number of
diseased segments, as scored on the case-record forms, and
even lower when compared with the angiographic assess-
ment by the core laboratory. Some segments were left
untreated because they were not scored as containing
angiographically severe lesions by the investigators. Accord-
ing to the case-record form, the number of segments treated
in the surgical group was not significantly different for the
complete and incomplete revascularization groups (Table 2).
For the stented angioplasty group, however, the number of
(successfully) treated segments, according to the central
reading of the angiograms, was significantly lower in the
incompletely revascularized group (Table 2).
Table 3 summarizes the major adverse events, in rank
order, for the four subgroups. A significantly higher rate of
event-free survival could be demonstrated only for the
completely versus the incompletely stented patients, due to
a significantly lower number of subsequent bypass opera-
tions.
On average, 1.4 lesions in patients from the incompletely
stented group were left untouched (66%) or resulted in a
failure (34%). This is significantly higher than the average of
1.1 segments left untreated by the surgeon (p  0.05). In
addition, more main branches were left untouched or were
unsuccessfully dilated in the incompletely stented group
compared with the incompletely bypassed group (Table 4).
No differences in infarct-free and stroke-free survival
could be demonstrated among the four groups (Fig. 1A).
When repeat revascularizations were also considered, a
significant difference in event-free survival could be dem-
onstrated between completely and incompletely revascular-
Table 2. Extent of Coronary Artery Disease and Subsequent Treatment According to the CRF and the Angiographic ACL
CABG PTCA/Stenting
Complete Incomplete Complete Incomplete
Vessels diseased per CRF 2.3  0.5 2.5  0.5* 2.3  0.5 2.4  0.5†
Vessels diseased per AACL 2.3  0.5 2.7  0.5* 2.2  0.4 2.5  0.5*
Segments diseased per CRF 2.7  0.9 3.1  1.1* 2.8  1.0 2.9  1.0
Segments diseased per AACL 2.6  0.8 3.7  1.1* 2.5  0.6 3.4  1.1*
Patients with 1 total occlusions 12.4% 26.7%* 5.4% 19.4%*
Segments treated per CRF 2.8  0.8 2.6  0.8 2.6  0.9 2.3  1.0*
Segments successfully treated per AACL 2.5  0.6 2.0  0.7*
*p  0.001 incomplete vs. complete. †p  0.01 incomplete vs. complete. Data are presented as the mean value  SD or percentage of patients.
AACL  angiographic assessment by the core laboratory; CRF  case record form. Rest of abbreviations as in Table 1.
Table 1. Baseline Demographics and Patient Characteristics Included in the Assessment of










Gender, male 76.9% 68.9% 76.1% 79.4%
Age (yrs) 61  9 62  10 61  10 61  10
Stable angina 58.7% 58.9% 57.1% 55.9%
Unstable angina 36.3% 38.9% 36.5% 40.0%
Previous infarct 42.8% 36.7% 44.6% 42.9%
Diabetes 15.1% 23.3%* 17.7% 19.4%
*p  0.06. Data are presented as the percentage of patients or mean value  SD.
CABG  coronary artery bypass graft surgery; PTCA  percutaneous transluminal coronary angioplasty.
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ized patients from the stented angioplasty group, as well as
between the stented angioplasty groups and both surgical
groups (Fig. 1B). Overall, superior major adverse cardiovas-
cular or cerebrovascular events-free survival was evident
after bypass surgery, whether complete or incomplete, com-
pared with both complete and incomplete stented angio-
plasty.
DISCUSSION
Incomplete revascularization is known to have a negative
influence on the outcome after bypass surgery (14–17).
After percutaneous angioplasty, this adverse relationship is
much less clear (18–27). There may be several reasons for
this discrepancy, including the definition and assessment of
completeness of revascularization, the patients studied and
the duration of follow-up. If the usual definition for
completeness of revascularization is applied to the stented
angioplasty patients (25), complete revascularization was
present in 70% of the stented angioplasty patients. This
compares favorably with previous reports on the complete-
ness of percutaneous revascularization in two other random-
ized trials of angioplasty versus surgery (8,9), but it was
nevertheless somewhat disappointing for modern-day per-
cutaneous coronary interventions.
Comparison and assessment of completeness of revascu-
larization. In the BARI trial, complete revascularization
was attempted in only 584 (64%) of 907 patients random-
ized to angioplasty, but the percentage of patients who were
actually completely revascularized is not mentioned. In
CABRI, only 29% of all angioplasty patients had complete
revascularization (9). In contrast to the ARTS trial, BARI
and CABRI did not aim to achieve equivalency in the
degree of completeness of revascularization in both patient
groups. At five years in BARI, this led to a non-significant










Death 12 (2.5%) 4 (4.4%) 7 (1.7%) 6 (3.5%)
CVA 9 (1.9%) 0 7 (1.7%) 2 (1.2%
MI 16 (3.4%) 4 (4.4%) 20 (4.9%) 10 (5.9%)
Q-wave 16 (3.4%) 4 (4.4%) 17 (4.2%) 9 (5.3%)
Non–Q-wave 0 0 3 (0.7%) 1 (0.6%)
Repeat CABG 1 (0.2%) 1 (1.1%) 8 (2.0%) 17 (10.0%)*
Repeat PTCA 10 (2.1%) 2 (2.2%) 53 (13.1%) 17 (10.0%)
No MACCE 429 (89.9%) 79 (87.8%) 311 (76.6%) 118 (69.4%)*
*p  0.05 PTCA/stenting incomplete vs. PTCA stenting complete. Data are presented as the number (%) of patients.
CVA  cerebrovascular accident; MI  myocardial infarction; MACCE  major adverse cardiovascular or cerebrovascular events; other abbreviations as in Table 1.
Table 4. Extent and Quality of Incompleteness in Both Groups
Treated With Bypass Operation or Stented Angioplasty





Diseased vessels, average 2.7  0.5 2.5  0.5
Diseased segments, average 3.7  1.1 3.4  1.1
Successfully treated segments,
average
2.6  0.8 2.0  0.7*
Untreated segments*
Main branch only 24 (27%) 60 (35%)
Side branches only 63 (70%) 85 (50%)
Main and side branches 3 (3%) 25 (15%)
*p  0.01 PTCA/stenting vs. CABG. Data are presented as the mean value  SD or
number (%) of patients.
Abbreviations as in Tables 1 and 2.
Figure 1. (A) Freedom from death, myocardial infarction (MI) or cere-
brovascular accident (CVA) within one year, after complete or incomplete
revascularization with coronary artery bypass graft surgery (CABG) or
percutaneous transluminal coronary angioplasty (PTCA) stenting. (B)
Event-free survival in the four subgroups, also including repeat revascular-
ization as an event.
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difference in mortality of 4.6% between surgically treated
patients and incompletely revascularized angioplasty pa-
tients, compared with a mortality difference of 1.1% be-
tween surgically treated patients and those with intended
complete revascularization by angioplasty. The only other
difference that approached significance was the percentage
of patients undergoing bypass surgery within five years after
angioplasty, which was 29.7% versus 36% for those with
planned complete versus incomplete revascularization.
In the CABRI angioplasty cohort, after one year, the
completely revascularized patients had a higher event-free
survival, compared with incompletely revascularized patients
(69% vs. 57%; p  0.01). The same trend toward a higher
mortality rate exists for incompletely revascularized patients
in the ARTS trial, in both the stented angioplasty and
surgically treated groups. Although our study extends to
only one-year follow-up, the difference in event-free survival
was already present at hospital discharge after the initial
procedure. In fact, two-thirds of all bypass operations after
an incomplete angioplasty procedure were performed during
the initial hospital stay.
Assessment of the completeness of revascularization may
be an important issue. Generally, all bypass operations are
considered by the surgeon to be complete, but early closure
of a certain percentage of bypass grafts is well documented.
Thus, revascularization by 30 days after the procedure may
not be as complete as assumed by the surgeon at the time of
the operation. Angioplasty, by its very nature, is easier to
evaluate critically with respect to the completeness of
revascularization. Incomplete revascularization may be due
to lesions that are not amenable to angioplasty (e.g., totally
occluded small branches with adverse characteristics), but it
may also be due to a generous interpretation of the post-
procedural angiogram by the operator. It is well known that
assessment of procedures by core laboratories not directly
involved with patient enrollment may lead to outcome
scores different from those reported by the operator (28,29).
For example, in the GUSTO-IIb (Global Use of Strategies
To Open occluded arteries in acute coronary syndromes)
study, the core laboratory scored an additional 14% of
procedures as being unsuccessful, because at the end of the
intervention, the lesion severity still exceeded the 50%
diameter stenosis criterion.
In this study, when all of the diagnostic angiograms of the
patients randomized to surgery or stented angioplasty were
read centrally, many patients were scored as being incom-
pletely revascularized. This assessment for surgical patients
was done by comparing the diagnostic angiogram score with
the investigator’s surgical procedure report. For stented
angioplasty patients, the assessment of the completeness of
revascularization was achieved by comparing the diagnostic
angiogram with the post-procedural angiogram. This pro-
vided a much more stringent evaluation of the completeness
of revascularization than that in the surgical group. Thus,
accurate and reliable scoring of the completeness of surgical
revascularization cannot be guaranteed, because only repeat
angiography of all patients immediately after surgery can
provide such information, and this would be very difficult to
justify.
Patient selection. Incompletely revascularized stented pa-
tients showed more extensive coronary artery disease than
the completely revascularized angioplasty patients in ARTS.
In BARI, this difference in significantly diseased segments
was 3.9 versus 3.2, and in our study, it was 3.4 versus 2.5,
according to the core laboratory reading (8). In addition, the
number of patients with at least one totally occluded
segment was 30% higher in the incompletely revascularized
group in BARI. In our study, the total number of patients
with at least one total occlusion was much lower than that
in BARI, reflecting the intention of complete and compa-
rable revascularization in ARTS for the surgery and stented
angioplasty groups. Nevertheless, in our study, the fre-
quency of totally occluded segments was 14% higher in the
incompletely revascularized groups. Thus, both the more
extensive coronary artery disease and the higher percentage
of totally occluded segments contribute to a lower percent-
age of patients with complete revascularization. Unexpect-
edly, this was also true for patients treated with bypass
surgery.
Duration of follow-up. One of the shortcomings of our
study is the relatively short duration (one year) of follow-up.
Nevertheless, most events after angioplasty occur in the first
year, and a significant difference in event-free survival was
obvious between completely and incompletely revascular-
ized patients in the stented angioplasty group. With a
comparable gender mix and age distribution of patients
studied in BARI and ARTS, and a higher percentage of
diabetic and unstable patients in BARI—but with similar
left ventricular function, the “natural” history without inter-
vention might be expected to be comparable for patients
enrolled in these two studies. Nevertheless, the difference in
the incidence of bypass surgery procedures after complete
angioplasty in the two studies is striking: 2% in ARTS after
one year and 29.7% in BARI after five years.
Part of this difference in the repeat intervention rate can
undoubtedly be ascribed to a reduction in restenosis by the
implantation of stents in the ARTS trial (in 89% of all
dilated lesions). The number of repeat angioplasties consti-
tuted 13.1% in ARTS within one year, 24.1% in BARI
within five years and 21.6% in CABRI within one year
(2,5). Progression of atherosclerosis between one and five
years was an important reason for subsequent bypass surgery
in BARI, possibly coupled with a greater tendency to opt for
surgery as opposed to repeat angioplasty with stenting in
1995. Further developments in anti-restenosis therapy (e.g.,
brachytherapy, drug-eluting stents) may offer continued
percutaneous options in patients with restenosis or in-stent
restenosis after initially successful percutaneous procedures,
so that bypass surgery is no longer the only option available
to such patients.
Conclusions. The design of the ARTS trial was such that
at least two lesions in arteries 2.75 mm, leading to two
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different territories, had to be treated. Despite intentional
comparable revascularization, completeness was achieved in
84.1% of bypass patients and 70.5% of stented angioplasty
patients, according to a central angiographic core laboratory
assessment. After one year, this led to 7% and 2% lower
event-free survival rates for incompletely revascularized
patients from the stented angioplasty and surgically treated
cohorts, respectively, when compared with completely re-
vascularized patients allocated to the same treatment. This
means that for angioplasty patients, the effectiveness and
cost-effectiveness can be further enhanced by careful selec-
tion of patients, making complete revascularization the aim
and the outcome of the procedure.
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